Total revenue was $155.9 million, an increase of $19.9 million, or 15%, compared with $136.0 million in the second quarter of 2017
“We executed well operationally and delivered strong business results this quarter and in the first half of the year, all while closing our largest acquisition to date,” said Tarek Sherif, chairman and chief executive officer, Medidata. “Providing the life sciences industry a next gen analytics solution for commercialization, and the addition of leading edge, real world evidence capabilities as part of our platform, positions Medidata to be the strategic partner for customers pursuing digital transformation.”
Second Quarter 2018 Results
- Total revenue was $155.9 million, an increase of $19.9 million, or 15%, compared with $136.0 million in the second quarter of 2017
- Subscription revenue was $130.5 million, an increase of $17.6 million, or 16%, compared with the same period last year. Professional services revenue was $25.4 million, an increase of $2.3 million, or 10%, compared with $23.1 million in the second quarter of 2017
- GAAP operating income was $12.8 million, up 1%, compared with $12.7 million in the second quarter of 2017. Non-GAAP operating income1 was $36.6 million, up 18%, compared with $31.0 million a year ago
- GAAP net income was $16.6 million, or $0.27 per diluted share, up 120%, compared with $7.5 million, or $0.13 per diluted share, in the second quarter of 2017. Non-GAAP net income1 was $26.4 million, or $0.43 per diluted share, up 46%, compared with $18.1 million, or $0.30 per diluted share, in the second quarter of 2017. See the non-GAAP reconciliation included in this release for full details of the non-GAAP adjustments
- GAAP net income includes a gain of $7.6 million on the company’s original investment in SHYFT
- Total cash and marketable securities were $477.4 million at the end of the quarter, compared with $663.3 million on December 31, 2017
- Remaining 2018 adjusted subscription backlog2 as of June 30, 2018 was $263 million, an increase of $40 million, or 18%, compared with a year ago
Additional Highlights:
- IDC’s report (Worldwide Life Science Software Market Shares, 2017), published this June, names Medidata as the global leader in Life Science Development Software revenue. The report cites that Medidata has extended its leadership position.
- Novartis partnered with SHYFT to support the commercialization of key therapies in Europe with insights-based analytics
- Medidata delivered the industry’s largest Synthetic Control Database in Acute Myeloid Leukemia (AML) to a top pharma company. This targeted approach highlights the breadth and value of the company’s clinical data repository.
- Three top 25 pharma customers added RAVE Imaging to their existing enterprise agreements, indicating how Medidata enables companies to address the increasing use of medical imaging in clinical trials
- A top 10 pharma customer adopted Edge Site Payments as their global payments platform
- On average, contracts were renewed at 24% above prior value on a trailing twelve-month basis
"We are on track to achieve our financial targets,” said Rouven Bergmann, chief financial officer, Medidata. “Our competitive position has never been stronger, with the acquisition of SHYFT and continued excellent enterprise renewal performance. On top of this, we increased EBITDAO by over 20% year to date.”
For the full year 2018, the company's guidance provided on June 12, 2018 is unchanged. Please refer to the reconciliation of forward-looking guidance included in this release for full details of the non-GAAP adjustments.
|
Conference call details: |
||
|
Time: |
Today, July 24, 8 a.m. ET |
|
|
Live dial-in: |
1-877-303-2528, domestic |
|
|
1-847-829-0023, international |
||
|
Webcast: |
investor.mdsol.com |
|
|
Replay: |
1-800-585-8367, domestic |
|
| 1-404-537-3406, international | ||
| Passcode: 7399978 | ||
About Medidata
Medidata is leading the digital transformation of life sciences with the world's most-used platform for clinical development, commercial and real-world data. Powered by artificial intelligence and delivered by #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com
Cautionary Statement
Certain statements made in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Medidata Solutions, Inc. (“Medidata”), including, but not limited to, statements about Medidata’s forecast of financial performance, products and services, business model, strategy and growth opportunities, and competitive position. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. Among other things, the risks and uncertainties include, those associated with possible fluctuations in our financial and operating results; integration activities, performance and financial impact of acquired companies; our ability to retain and expand our customer base or increase new business from those customers; our ability to continue to release, and gain customer acceptance of, new and improved versions of our products. For additional disclosure regarding these and other risks faced by Medidata, see disclosures contained in Medidata’s public filings with the Securities and Exchange Commission, including the “Risk Factors” section of Medidata’s Annual Report on Form 10-K for the year ended December 31, 2017. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and Medidata undertakes no obligation to update such statements as a result of new information, new developments or otherwise, except as required by law.
(1) Non-GAAP Financial Information
Medidata provides non-GAAP operating income, net income, and net income per share data as a supplement to its operating results. These measures are not in accordance with, or an alternative to, generally accepted accounting principles (GAAP), and may be different from non-GAAP measures used by other companies. Management uses these non-GAAP measures to evaluate its financial results, develop budgets, manage expenditures, and as an important factor in determining variable compensation. In addition, management believes, based on discussions with investors, that these non-GAAP measures enhance investors’ ability to assess Medidata’s historical and projected future financial performance. While management believes these non-GAAP financial measures provide useful supplemental information to investors, there are inherent limitations associated with the use of non-GAAP financial measures. Investors are encouraged to review the attached reconciliations of these non-GAAP financial measures to the nearest comparable GAAP measures.
(2) Adjusted subscription backlog equals subscription backlog plus outstanding intra-year renewals valued at an amount equal to the contracts to be renewed.
| MEDIDATA SOLUTIONS, INC. | ||||||||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||||||||||||||
| (Amounts in thousands, except per share data) | ||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Subscription | $ | 130,486 | $ | 112,904 | (3 | ) | $ | 257,305 | $ | 220,797 | (3 | ) | ||||||||
| Professional services | 25,419 | 23,123 | 47,798 | 42,874 | ||||||||||||||||
| Total revenues | 155,905 | 136,027 | 305,103 | 263,671 | ||||||||||||||||
| Cost of revenues (1)(2) | ||||||||||||||||||||
| Subscription | 21,602 | 17,017 | 41,943 | 34,146 | ||||||||||||||||
| Professional services | 15,899 | 14,903 | 31,860 | 28,388 | ||||||||||||||||
| Total cost of revenues | 37,501 | 31,920 | 73,803 | 62,534 | ||||||||||||||||
| Gross profit | 118,404 | 104,107 | 231,300 | 201,137 | ||||||||||||||||
| Operating costs and expenses | ||||||||||||||||||||
| Research and development (1) | 40,789 | 35,884 | 78,311 | 65,821 | ||||||||||||||||
| Sales and marketing (1)(2) | 37,106 | 32,479 | (3 | ) | 73,967 | 62,705 | (3 | ) | ||||||||||||
| General and administrative (1) | 27,672 | 23,083 | 52,859 | 47,071 | ||||||||||||||||
| Total operating costs and expenses | 105,567 | 91,446 | 205,137 | 175,597 | ||||||||||||||||
| Operating income | 12,837 | 12,661 | 26,163 | 25,540 | ||||||||||||||||
|
Interest and other income (expense) |
||||||||||||||||||||
| Interest expense | (5,700 | ) | (4,383 | ) | (11,275 | ) | (8,710 | ) | ||||||||||||
| Interest income | 2,328 | 1,328 | 4,416 | 2,499 | ||||||||||||||||
| Other income, net | 7,729 | — | 7,633 | — | ||||||||||||||||
| Total interest and other income (expense), net | 4,357 | (3,055 | ) | 774 | (6,211 | ) | ||||||||||||||
| Income before income taxes | 17,194 | 9,606 | 26,937 | 19,329 | ||||||||||||||||
| Provision for income taxes | 605 | 2,065 | (3 | ) | 23 | 1,808 | (3 | ) | ||||||||||||
| Net income | $ | 16,589 | $ | 7,541 | (3 | ) | $ | 26,914 | $ | 17,521 | (3 | ) | ||||||||
| Earnings per share | ||||||||||||||||||||
| Basic | $ | 0.29 | $ | 0.13 | (3 | ) | $ | 0.47 | $ | 0.31 | (3 | ) | ||||||||
| Diluted | $ | 0.27 | $ | 0.13 | (3 | ) | $ | 0.44 | $ | 0.30 | (3 | ) | ||||||||
| Weighted average common shares outstanding | ||||||||||||||||||||
| Basic | 57,448 | 56,433 | 57,252 | 56,254 | ||||||||||||||||
| Diluted | 60,874 | 59,835 | 60,564 | 59,051 | ||||||||||||||||
| (1) Stock-based compensation expense included in cost of revenues and operating costs and expenses is as follows: | ||||||||||||||||||||
| Cost of revenues | $ | 1,506 | $ | 1,246 | $ | 2,774 | $ | 2,415 | ||||||||||||
| Research and development | 3,319 | 3,427 | 6,173 | 6,262 | ||||||||||||||||
| Sales and marketing | 2,917 | 1,836 | 5,561 | 3,011 | ||||||||||||||||
| General and administrative | 7,377 | 6,183 | 13,766 | 11,325 | ||||||||||||||||
| Total stock-based compensation | $ | 15,119 | $ | 12,692 | $ | 28,274 | $ | 23,013 | ||||||||||||
| (2) Amortization of intangible assets included in costs of revenues and operating costs and expenses is as follows: | ||||||||||||||||||||
| Cost of revenues | $ | 1,205 | $ | 1,022 | $ | 2,299 | $ | 1,476 | ||||||||||||
| Sales and marketing | 231 | 119 | 351 | 202 | ||||||||||||||||
| Total amortization of intangible assets | $ | 1,436 | $ | 1,141 | $ | 2,650 | $ | 1,678 | ||||||||||||
| (3) Figures for the three and six months ended June 30, 2017 have been recast to reflect our January 1, 2018 full retrospective adoption of Accounting Standards Codification ("ASC") 606. | ||||||||||||||||||||
| MEDIDATA SOLUTIONS, INC. | ||||||||||||||||||||
|
Reconciliation of GAAP Operating Income and GAAP Net Income to Non-GAAP Operating Income and Non-GAAP Net Income (Unaudited) |
||||||||||||||||||||
| (Amounts in thousands, except per share data) | ||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||||||
| Operating income: | ||||||||||||||||||||
| GAAP operating income | $ | 12,837 | $ | 12,661 | (6 | ) | $ | 26,163 | $ | 25,540 | (6 | ) | ||||||||
| GAAP operating margins | 8.2 |
% |
9.3 | % | (6 | ) | 8.6 | % | 9.7 | % | (6 | ) | ||||||||
| Stock-based compensation | 15,119 | 12,692 | 28,274 | 23,013 | ||||||||||||||||
| Depreciation and amortization | 8,405 | 5,589 | 16,218 | 10,065 | ||||||||||||||||
| Contingent consideration adjustment (1) | 79 | 58 | 7 | 58 | ||||||||||||||||
| Cash compensation from acquisition-related agreements (2) | 134 | — | 134 | — | ||||||||||||||||
| Non-GAAP operating income | $ | 36,574 | $ | 31,000 | (6 | ) | $ | 70,796 | $ | 58,676 | (6 | ) | ||||||||
| Non-GAAP operating margins | 23.5 | % | 22.8 | % | (6 | ) | 23.2 | % | 22.3 | % | (6 | ) | ||||||||
| Net income: | ||||||||||||||||||||
| GAAP net income | $ | 16,589 | $ | 7,541 | (6 | ) | $ | 26,914 | $ | 17,521 | (6 | ) | ||||||||
| Stock-based compensation | 15,119 | 12,692 | 28,274 | 23,013 | ||||||||||||||||
| Amortization | 1,436 | 1,141 | 2,650 | 1,678 | ||||||||||||||||
| Contingent consideration adjustment (1) | 79 | 58 | 7 | 58 | ||||||||||||||||
| Cash compensation from acquisition-related agreements (2) | 134 | — | 134 | — | ||||||||||||||||
| Non-cash interest expense (3) | 3,963 | 3,648 | 7,871 | 7,246 | ||||||||||||||||
| Gain on step acquisition (4) | (7,648 | ) | — | (7,648 | ) | — | ||||||||||||||
| Tax impact on add-back items (5) | (3,271 | ) | (7,016 | ) | (7,822 | ) | (12,798 | ) | ||||||||||||
|
Non-GAAP net income |
$ | 26,401 | $ | 18,064 | (6 | ) | $ | 50,380 | $ | 36,718 | (6 | ) | ||||||||
| GAAP basic earnings per share | $ | 0.29 | $ | 0.13 | (6 | ) | $ | 0.47 | $ | 0.31 | (6 | ) | ||||||||
| GAAP diluted earnings per share | $ | 0.27 | $ | 0.13 | (6 | ) | $ | 0.44 | $ | 0.30 | (6 | ) | ||||||||
|
Non-GAAP basic earnings per share |
$ | 0.46 | $ | 0.32 | (6 | ) | $ | 0.88 | $ | 0.65 | (6 | ) | ||||||||
|
Non-GAAP diluted earnings per share |
$ | 0.43 | $ | 0.30 | (6 | ) | $ | 0.83 | $ | 0.62 | (6 | ) | ||||||||
| (1) Change in fair value of acquisition-related contingent consideration liabilities. |
| (2) Expense associated with acquisition-related cash compensation agreements entered into with certain employees of SHYFT Analytics, Inc. ("SHYFT"). |
| (3) Non-cash interest expense includes amortization of debt discount and issuance costs on our 1.00% convertible senior notes issued in 2013 and amortization of issuance costs on our credit agreement entered into in 2017. We exclude this incremental non-cash interest expense for purposes of calculating non-GAAP net income. We believe that excluding these expenses from our non-GAAP measures is useful to investors because such incremental non-cash interest expense does not generate a cash outflow, nor do the debt issuance costs represent a cash outflow except in the period of issuance; therefore both are not indicative of our continuing operations. |
| (4) Elimination of gain recognized upon step acquisition of SHYFT. |
| (5) Tax impact calculated using tax rates of 25% and 40% for the periods ended June 30, 2018 and 2017, respectively. |
| (6) Figures for the three and six months ended June 30, 2017 have been recast to reflect our January 1, 2018 full retrospective adoption of ASC 606. |
|
The table above presents a reconciliation of GAAP to non-GAAP operating income, net income, and net income per share applicable to common stockholders for the three and six months ended June 30, 2018 and 2017. Non-GAAP operating income excludes the impact of stock-based compensation, depreciation, amortization of intangible assets associated with acquisitions, adjustments to the fair value of contingent consideration, and cash compensation from acquisition-related agreements. Non-GAAP net income excludes the tax-affected impact of stock-based compensation, amortization of intangible assets associated with acquisitions, adjustments to the fair value of contingent consideration, cash compensation from acquisition-related agreements, non-cash interest expense, and gain on step acquisition. |
| MEDIDATA SOLUTIONS, INC. | ||||||||
| CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||||
| (Amounts in thousands, except per share data) | ||||||||
|
June 30, |
December 31, |
|||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 120,298 | $ | 237,325 | ||||
| Marketable securities | 287,603 | 246,967 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $1,668 and $1,454, respectively | 137,169 | 110,685 | ||||||
| Prepaid commission expense | 17,612 | 12,404 | ||||||
| Prepaid expenses and other current assets | 37,109 | 33,636 | ||||||
| Total current assets | 599,791 | 641,017 | ||||||
| Restricted cash | 5,523 | 5,518 | ||||||
| Furniture, fixtures and equipment, net | 93,088 | 88,091 | ||||||
| Marketable securities, long-term | 69,476 | 179,041 | ||||||
| Goodwill | 198,780 | 47,435 | ||||||
| Intangible assets, net | 54,938 | 17,587 | ||||||
| Deferred income taxes, long-term | 37,414 | 35,789 | ||||||
| Other assets | 43,775 | 46,755 | ||||||
| Total assets | $ | 1,102,785 | $ | 1,061,233 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 6,527 | $ | 5,009 | ||||
| Accrued payroll and other compensation | 23,061 | 32,537 | ||||||
| Accrued expenses and other | 37,624 | 36,041 | ||||||
| Deferred revenue | 72,075 | 77,375 | ||||||
| 1.00% convertible senior notes, net | 285,748 | 278,094 | ||||||
| Total current liabilities | 425,035 | 429,056 | ||||||
| Noncurrent liabilities: | ||||||||
| Term loan, net | 91,906 | 92,841 | ||||||
| Deferred revenue, less current portion | 3,993 | 5,256 | ||||||
| Deferred tax liabilities | 100 | 99 | ||||||
| Other long-term liabilities | 20,395 | 21,371 | ||||||
| Total noncurrent liabilities | 116,394 | 119,567 | ||||||
| Total liabilities | 541,429 | 548,623 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred stock, par value $0.01 per share; 5,000 shares authorized, none issued and outstanding | — | — | ||||||
| Common stock, par value $0.01 per share; 200,000 shares authorized; 64,289 and 62,801 shares issued; 59,634 and 58,607 shares outstanding, respectively | 643 | 628 | ||||||
| Additional paid-in capital | 527,336 | 486,147 | ||||||
| Treasury stock, 4,655 and 4,194 shares, respectively | (150,964 | ) | (132,705 | ) | ||||
| Accumulated other comprehensive loss | (4,490 | ) | (3,377 | ) | ||||
| Retained earnings | 188,831 | 161,917 | ||||||
| Total stockholders' equity | 561,356 | 512,610 | ||||||
| Total liabilities and stockholders' equity | $ | 1,102,785 | $ | 1,061,233 | ||||
| MEDIDATA SOLUTIONS, INC. | ||||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | ||||||||||
| (Amounts in thousands) | ||||||||||
| Six Months Ended June 30, | ||||||||||
| 2018 | 2017 | |||||||||
| Cash flows from operating activities | ||||||||||
| Net income | $ | 26,914 | $ | 17,521 | (1 | ) | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Amortization of intangible assets and depreciation | 16,218 | 10,065 | ||||||||
| Stock-based compensation | 28,274 | 23,013 | ||||||||
| Amortization of discounts or premiums on marketable securities | 50 | 757 | ||||||||
| Deferred income taxes | 106 | 2,406 | (1 | ) | ||||||
| Amortization of debt issuance costs | 856 | 639 | ||||||||
| Amortization of debt discount | 7,015 | 6,607 | ||||||||
| Provision for doubtful accounts | 763 | 526 | ||||||||
| Loss (gain) on fixed asset disposal | 127 | (2 | ) | |||||||
| Gain recognized on step acquisition | (7,648 | ) | — | |||||||
| Changes in fair value of contingent consideration | 7 | 58 | ||||||||
| Changes in operating assets and liabilities: | ||||||||||
| Accounts receivable | (27,247 | ) | 4,058 | |||||||
| Prepaid commission expense | (7,205 | ) | (5,514 | ) | (1 | ) | ||||
| Prepaid expenses and other current assets | (3,008 | ) | (12,366 | ) | (1 | ) | ||||
| Other assets | 1,591 | 1,171 |
|
|
||||||
| Accounts payable | 1,753 | 4,490 | ||||||||
| Accrued payroll and other compensation | (8,909 | ) | (10,122 | ) | ||||||
| Accrued expenses and other | (764 | ) | 5,313 | |||||||
| Deferred revenue | (9,572 | ) | 11,198 | (1 | ) | |||||
| Other long-term liabilities | 4,455 | 884 | ||||||||
| Net cash provided by operating activities | 23,776 | 60,702 | ||||||||
| Cash flows from investing activities | ||||||||||
| Purchase of furniture, fixtures and equipment | (19,520 | ) | (16,642 | ) | ||||||
| Purchase of available-for-sale securities | (69,214 | ) | (157,228 | ) | ||||||
| Proceeds from sale of available-for-sale securities | 137,786 | 154,117 | ||||||||
| Acquisition of businesses, net of cash acquired | (178,568 | ) | (22,941 | ) | ||||||
| Net cash used in investing activities | (129,516 | ) | (42,694 | ) | ||||||
| Cash flows from financing activities | ||||||||||
| Proceeds from exercise of stock options | 6,351 | 9,057 | ||||||||
| Proceeds from employee stock purchase plan | 6,345 | 4,248 | ||||||||
| Acquisition of treasury stock | (18,257 | ) | (14,785 | ) | ||||||
| Term loan principal payments | (1,250 | ) | — | |||||||
| Payment of acquisition-related earn-outs | (4,087 | ) | — | |||||||
| Payment of credit facility financing costs | (175 | ) | — | |||||||
| Net cash used in financing activities | (11,073 | ) | (1,480 | ) | ||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (209 | ) | 414 | |||||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (117,022 | ) | 16,942 | |||||||
| Cash, cash equivalents and restricted cash – Beginning of period | 242,843 | 99,279 | ||||||||
|
Cash, cash equivalents and restricted cash – End of period |
$ | 125,821 | $ | 116,221 | ||||||
| (1) Figures for the six months ended June 30, 2017 have been recast to reflect our January 1, 2018 full retrospective adoption of ASC 606. | ||||||||||
| MEDIDATA SOLUTIONS, INC. | ||||
|
Reconciliation of Forward-Looking GAAP Operating Income Guidance and GAAP Net Income Guidance to Non-GAAP Operating Income Guidance and Non-GAAP Net Income Guidance (Unaudited) |
||||
| (Amounts in millions) | ||||
| Estimated Full-Year 2018 | ||||
| Total revenues | $ | 624.0 - $648.0 | ||
| GAAP operating income: | $ | 45.5- $53.5 | ||
| Stock-based compensation (1) | 64.0 | |||
| Depreciation and amortization (1) | 34.0 | |||
| Contingent consideration adjustment (1) | 0.5 | |||
| Cash compensation from acquisition-related agreements (1) | 2.0 | |||
| Non-GAAP operating income | $ | 146.0 - $154.0 | ||
| GAAP net income: | $ | 28.5 - $35.5 | ||
| Stock-based compensation (1) | 64.0 | |||
| Amortization (1) | 6.0 | |||
| Non-cash interest expense (1) | 10.0 | |||
| Contingent consideration adjustment (1) | 0.5 | |||
| Cash compensation from acquisition-related agreements (1) | 2.0 | |||
| Tax impact on add-back items (2) | (20.5 | ) | ||
|
Non-GAAP net income |
$ | 90.5 - $97.5 | ||
| Fully diluted share count | 61.0 | |||
| (1) Represents the estimated midpoint of our guidance range. | ||||
| (2) Tax impact estimated using a 25% rate. | ||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20180724005279/en/
Contacts
Medidata Solutions
Investor:
Betsy Frank, 917-522-4620
bfrank@mdsol.com
or
Media:
Erik Snider, 646-362-2997
esnider@mdsol.com
Source: Medidata
View this news release online at:
http://www.businesswire.com/news/home/20180724005279/en
